Effect of Glucosamine on Joint Structure and Quality of Life (JOG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00377286|
Recruitment Status : Completed
First Posted : September 18, 2006
Last Update Posted : June 14, 2011
|Condition or disease||Intervention/treatment||Phase|
|Osteoarthritis||Dietary Supplement: Glucosamine (a dietary supplement) Other: 16 oz lite lemonade||Not Applicable|
Reduced knee function is a significant cause of physical limitations and disability. As cartilage deteriorates due to aging, wear-and-tear, injury, or disease, joint space narrowing and pain can develop. The lost of articular cartilage arises from an imbalance between cartilage synthesis and cartilage degradation. When cartilage needs to be remodeled, enzymes such as matrix metalloproteinases (MMPs) degrade type II collagen. It now may be possible to use new molecular markers of cartilage degradation to assess the progression of joint loss in comparison with radiographic changes of the knee joint. Urinary excretion of C-terminal cross linking telopeptide of type II collagen (CTX-II) is a new molecular marker of cartilage tissue degradation metabolism.
Recent evidence suggests that glucosamine, a dietary supplement, may provide some relief from joint pain and may increase the functional ability to participate in activities of daily living. This may be a result of these dietary supplements stimulating tissue repair such as cartilage in the affected joints, or by inhibiting the degradation of cartilage through an inhibition of enzymes. Moreover, Braham, Dawson, & Goodman (2003) reported increases in function in adults with knee pain following 12 -weeks of glucosamine supplementation. It is unclear, however, if glucosamine delivered via a liquid carrier would improve physical function and impact quality of life measures in people who have experienced loss of knee cartilage.
Glucosamine is a precursor for glycosaminoglycans, which are a major component of both joint cartilage and skin. Potential benefits of glucosamine on skin have been reported previously. It is possible that glucosamine in a beverage might also improve skin parameters over time.
Comparisons: 100 men and women with mild to moderate joint pain taking a liquid with glucosamine, compared to 100 men and women with mild to moderate joint pain taking a liquid with placebo.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||201 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Development of Biomarker and Functional Assessment Tools to Evaluate the Effect of Glucosamine on Joint Structure and Quality of Life|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||May 2008|
Placebo Comparator: 2
1500 mg of lite lemonade
Other: 16 oz lite lemonade
16 oz lite lemonade 1 time daily for 6 months
Other Name: Minute Maid
Active Comparator: 1
1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
Dietary Supplement: Glucosamine (a dietary supplement)
1500 mg in 16 oz lite lemonade, once per day for 6 months
- Urinary excretion of CTX-II at 3 and 6 months post intervention [ Time Frame: 3 and 6 months ]
- Measurement of bone marrow lesions, cartilage volume, as shown by MRI post intervention [ Time Frame: 6 month ]
- Scores on WOMAC and KOOS of knee pain and function [ Time Frame: 3 and 6 months ]
- Scores on performance measures [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00377286
|United States, Pennsylvania|
|University of Pittsburgh|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||John Jakicic, PhD||University of Pittsburgh|
|Principal Investigator:||C. Kent Kwoh, M.D.||University of Pittsburgh|